Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization
Introduction:Recent studies have demonstrated the promise of emergency department (ED)-initiated buprenorphine/naloxone (bup/nx) for improving 30-day retention in outpatient addiction care programs for patients with opioid use disorder (OUD). We investigated whether ED-initiated bup/nx for OUD also impacts repeat ED utilization.Methods: We performed a retrospective chart review of ED patients discharged with a primary diagnosis of OUD from July 2019 –December 2020. Characteristics considered included age, gender, race, insurance status, domicile status, presence of comorbid Diagnostic and Statistical Manual of Mental Dis...
Source: Western Journal of Emergency Medicine - November 8, 2023 Category: Emergency Medicine Authors: Skains, Rachel M. Source Type: research
A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder
This article briefly discusses the opioid epidemic and the diagnosis and treatment of opioid use disorder (OUD). We then describe the basic and complex pharmacologic propertie s of buprenorphine, linking these properties to their clinical implications. We guide readers through the process of initiating buprenorphine in patients using full agonist opioids. As there is no single recommended approach for buprenorphine initiation, we discuss the details, advantages, and disad vantages of the standard, low-dose, bridging-strategy, and naloxone-facilitated initiation techniques. We consider the pharmacology of, and evidence base...
Source: Drugs in R&D - November 8, 2023 Category: Drugs & Pharmacology Source Type: research
Evaluation of opioid use disorder treatment outcomes in patients receiving split daily versus once daily dosing of buprenorphine-naloxone
This study aims to evaluate how the dosing frequency of SL buprenorphine-naloxone impacts therapy effectiveness when treating patients with OUD. (Source: Journal of Substance Abuse Treatment)
Source: Journal of Substance Abuse Treatment - November 5, 2023 Category: Addiction Authors: Joshua B. Borris, Caitlin Dowd-Green, Lindsay A. Bowman, Suzanne A. Nesbit, Michael Fingerhood, Rosalyn W. Stewart Source Type: research
Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study
CONCLUSION: Methadone did not show a significant effect on overall non-opioid substance use in POUD compared to BUP/NX treatment but was associated with lower odds of benzodiazepine and THC use in particular. Non-opioid substance use did not predict OAT outcomes. Further research is needed to ascertain whether specific patterns of polysubstance use (quantity and frequency) may affect treatment outcomes.PMID:37899716 | DOI:10.1177/07067437231210796 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - October 30, 2023 Category: Psychiatry Authors: Hamzah Bakouni Heidar Sharafi Sarah Drouin Raphaelle Fortin St éphanie Marsan Suzanne Brissette Maria Eugenia Socias Bernard Le Foll Ron Lim Didier Jutras-Aswad Source Type: research
Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study
CONCLUSION: Methadone did not show a significant effect on overall non-opioid substance use in POUD compared to BUP/NX treatment but was associated with lower odds of benzodiazepine and THC use in particular. Non-opioid substance use did not predict OAT outcomes. Further research is needed to ascertain whether specific patterns of polysubstance use (quantity and frequency) may affect treatment outcomes.PMID:37899716 | DOI:10.1177/07067437231210796 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - October 30, 2023 Category: Psychiatry Authors: Hamzah Bakouni Heidar Sharafi Sarah Drouin Raphaelle Fortin St éphanie Marsan Suzanne Brissette Maria Eugenia Socias Bernard Le Foll Ron Lim Didier Jutras-Aswad Source Type: research
Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study
CONCLUSION: Methadone did not show a significant effect on overall non-opioid substance use in POUD compared to BUP/NX treatment but was associated with lower odds of benzodiazepine and THC use in particular. Non-opioid substance use did not predict OAT outcomes. Further research is needed to ascertain whether specific patterns of polysubstance use (quantity and frequency) may affect treatment outcomes.PMID:37899716 | DOI:10.1177/07067437231210796 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - October 30, 2023 Category: Psychiatry Authors: Hamzah Bakouni Heidar Sharafi Sarah Drouin Raphaelle Fortin St éphanie Marsan Suzanne Brissette Maria Eugenia Socias Bernard Le Foll Ron Lim Didier Jutras-Aswad Source Type: research
Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study
CONCLUSION: Methadone did not show a significant effect on overall non-opioid substance use in POUD compared to BUP/NX treatment but was associated with lower odds of benzodiazepine and THC use in particular. Non-opioid substance use did not predict OAT outcomes. Further research is needed to ascertain whether specific patterns of polysubstance use (quantity and frequency) may affect treatment outcomes.PMID:37899716 | DOI:10.1177/07067437231210796 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - October 30, 2023 Category: Psychiatry Authors: Hamzah Bakouni Heidar Sharafi Sarah Drouin Raphaelle Fortin St éphanie Marsan Suzanne Brissette Maria Eugenia Socias Bernard Le Foll Ron Lim Didier Jutras-Aswad Source Type: research
Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Daniel M Strickland Jordon T Baker Source Type: research
A qualitative study of chronic pain and opioid use: The impact of restrictive prescribing
CONCLUSIONS: Opioid use for CP is complex and multifaceted. The continuum of pain and opioid use disorder can begin with a prescription for acute pain and continue for the treatment of CP. Patients described how continued opioid use was not to "get high" but for pain control to improve their quality of life, continue to work, and be productive. For those who experience physical dependence on opioids, access to treatment is vital to recovery and pain management.KEY MESSAGE: Without individualized managed care, people confronted with a sudden interruption in prescription opioids may turn to illicit drugs to mitigate symptoms...
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Cara L Sedney Patricia Dekeseredy Marissa Davis Treah Haggerty Source Type: research
Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Daniel M Strickland Jordon T Baker Source Type: research
A qualitative study of chronic pain and opioid use: The impact of restrictive prescribing
CONCLUSIONS: Opioid use for CP is complex and multifaceted. The continuum of pain and opioid use disorder can begin with a prescription for acute pain and continue for the treatment of CP. Patients described how continued opioid use was not to "get high" but for pain control to improve their quality of life, continue to work, and be productive. For those who experience physical dependence on opioids, access to treatment is vital to recovery and pain management.KEY MESSAGE: Without individualized managed care, people confronted with a sudden interruption in prescription opioids may turn to illicit drugs to mitigate symptoms...
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Cara L Sedney Patricia Dekeseredy Marissa Davis Treah Haggerty Source Type: research
Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Daniel M Strickland Jordon T Baker Source Type: research
A qualitative study of chronic pain and opioid use: The impact of restrictive prescribing
CONCLUSIONS: Opioid use for CP is complex and multifaceted. The continuum of pain and opioid use disorder can begin with a prescription for acute pain and continue for the treatment of CP. Patients described how continued opioid use was not to "get high" but for pain control to improve their quality of life, continue to work, and be productive. For those who experience physical dependence on opioids, access to treatment is vital to recovery and pain management.KEY MESSAGE: Without individualized managed care, people confronted with a sudden interruption in prescription opioids may turn to illicit drugs to mitigate symptoms...
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Cara L Sedney Patricia Dekeseredy Marissa Davis Treah Haggerty Source Type: research
Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Daniel M Strickland Jordon T Baker Source Type: research
